心脏骤停患者ECMO-VA前的低温治疗:HYPO-ECMO试验的启示
该研究为HYPO-ECMO随机试验的非预设事后分析,纳入2016年10月至2019年7月法国20个心脏休克中心接受VA-ECMO的334例难治性心源性休克患者,随机分为早期中度低温(33-34°C)或常温(36-37°C)24小时。159例(48%)发生心脏骤停,其30天死亡率为50.9%、180天为59.1%,无心脏骤停组分别为42.3%和51.4%(校正风险差30天8.1%[-0.8至17.1%],p=0.074;180天7.0%[-3.0至16.9%],p=0.17)。仅在心脏骤停组中,中度低温与主要终点显著降低相关(RD -13.3%[-16.3至-0.3%],p=0.031),次要终点也显著降低(p<0.025),且180天死亡率存在显著交互作用(p=0.03)。作者认为中度低温可能减少心脏骤停合并难治性心源性休克接受VA-ECMO患者的死亡率和复合终点,不增加严重出血或感染风险,需进一步研究验证。
要点
- 在HYPO-ECMO试验的心脏骤停亚组中,中度低温(33-34°C)24小时与主要终点显著降低相关(RD -13.3%[-16.3至-0.3%],p=0.031)。
- 心脏骤停组30天死亡率为50.9%,无心脏骤停组为42.3%(校正RD 8.1%[-0.8至17.1%],p=0.074);180天死亡率分别为59.1%和51.4%(RD 7.0%[-3.0至16.9%],p=0.17)。
- 中度低温与心脏骤停状态对180天死亡率存在显著交互作用(p=0.03),提示低温效应仅限于心脏骤停患者。
- 心脏骤停组中,中度低温与次要终点也显著降低相关(p<0.025),且不增加严重出血或感染风险。
- 该分析为非预设事后分析,作者指出需进一步研究验证这些发现并阐明机制。
适用人群与场景
- 接受VA-ECMO治疗难治性心源性休克且插管时间小于6小时的患者,来自HYPO-ECMO随机试验的20个法国心脏休克中心。
- 本次事后分析聚焦于其中发生心脏骤停的亚组患者(159/334,48%)。
处置流程与药物剂量
- 患者随机接受早期中度低温(33-34°C)或常温(36-37°C)治疗,持续24小时。
研究设计与关键结果
- 研究类型:HYPO-ECMO随机试验的非预设事后分析,纳入2016年10月至2019年7月法国20个心脏休克中心的334例接受VA-ECMO的难治性心源性休克患者,159例(48%)有心脏骤停。
- 心脏骤停组30天死亡率为50.9%、180天为59.1%,无心脏骤停组分别为42.3%和51.4%;校正风险差30天8.1%[-0.8至17.1%],p=0.074;180天7.0%[-3.0至16.9%],p=0.17。
- 仅在心脏骤停组中,中度低温与主要终点显著降低相关(RD -13.3%[-16.3至-0.3%],p=0.031),次要终点也显著降低(p<0.025)。
- 中度低温与心脏骤停状态对180天死亡率存在显著交互作用(p=0.03)。
- 中度低温不增加严重出血或感染风险。
证据类型、等级与局限
- 证据类型:随机对照试验的非预设事后分析。
- 作者指出需进一步研究验证这些发现并阐明潜在机制。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于心脏骤停合并难治性心源性休克接受VA-ECMO治疗的患者,中度低温(33-34°C)可能降低死亡率和复合终点,且不增加严重出血或感染风险。
- 该分析为非预设事后分析,作者指出需进一步研究验证这些发现并阐明机制。
指南或共识出处
- HYPO-ECMO试验(发表于Resuscitation)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has become a common intervention for patients with cardiogenic shock (CS), often complicated by cardiac arrest (CA). Moderate hypothermia (MH) has shown promise in mitigating ischemia-reperfusion injury following CA. The HYPO-ECMO trial aimed to compare the effect of MH versus normothermia in refractory CS rescued by VA-ECMO. The primary aim of this non-predefined post hoc study was to assess the treatment effect of MH in the subgroup of patients with cardiac arrest (CA) within the HYPO-ECMO trial. Additionally, we will evaluate the prognostic significance of CA in these patients.
METHODS: This post hoc analysis utilized data from the randomized HYPO-ECMO trial conducted across 20 French cardiac shock care centers between October 2016 and July 2019. Participants included intubated patients receiving VA-ECMO for CS for less than 6 h, with 334 patients completing the trial. Patients were randomized to early MH (33-34 °C) or normothermia (36-37 °C) for 24 h.
RESULTS: Of the 334 patients, 159 (48%) experienced preceding CA. Mortality in the CA group was 50.9% at 30 days and 59.1% at 180 days, compared to 42.3% and 51.4% in the no-CA group, respectively (adjusted risk difference [RD] at 30 days, 8.1% [-0.8 to 17.1%], p = 0.074 and RD at 180 days 7.0% [-3.0 to 16.9%], p = 0.17). MH was associated with a significant reduction in primary (RD -13.3% [-16.3 to -0.3%], p = 0.031) and secondary outcomes in the CA group only (p < 0.025 for all), with a significant interaction between MH and CA status for 180-day mortality [p = 0.03].
CONCLUSIONS: This post hoc analysis suggests that MH shows potential for reducing mortality and composite endpoints in patients with cardiac arrest and refractory CS treated with VA-ECMO without an increased risk of severe bleeding or infection. Further research is needed to validate these findings and elucidate underlying mechanisms.
参考来源
- Levy B, Girerd N, Duarte K, et al. Hypothermia in patients with cardiac arrest prior to ECMO-VA: Insight from the HYPO-ECMO trial. Resuscitation. 2024. PMID: 38762081. doi:10.1016/j.resuscitation.2024.110235
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。